Salbutamol increases leg glucose uptake and metabolic rate but not muscle glycogen resynthesis in recovery from exercise
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Salbutamol increases leg glucose uptake and metabolic rate but not muscle glycogen resynthesis in recovery from exercise. / Onslev, Johan; Thomassen, Martin; Wojtaszewski, Jørgen; Bangsbo, Jens; Hostrup, Morten.
I: Journal of Clinical Endocrinology and Metabolism, Bind 107, Nr. 3, 2022, s. e1193-e1203.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Salbutamol increases leg glucose uptake and metabolic rate but not muscle glycogen resynthesis in recovery from exercise
AU - Onslev, Johan
AU - Thomassen, Martin
AU - Wojtaszewski, Jørgen
AU - Bangsbo, Jens
AU - Hostrup, Morten
N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2022
Y1 - 2022
N2 - Content: Exercise blunts the effect of beta2-agonist on peripheral glucose uptake and energy expenditure. Whether such attenuation extends into recovery is unknown.Objective: To examine the effect of beta2-agonist on leg glucose uptake and metabolic rate in recovery from exercise.Design: Using leg arteriovenous balance technique and analyses of thigh muscle biopsies, we investigated the effect of beta2-agonist (24 mg oral salbutamol) vs placebo on leg glucose, lactate, and oxygen exchange before, during, and 0.5-5-h in recovery from quadriceps exercise, as well as on muscle glycogen resynthesis and activity in recovery. Twelve healthy, lean young men participated.Results: Before exercise, leg glucose uptake was 0.42±0.12 and 0.20±0.02 mmol×min-1 (mean±SD) for salbutamol and placebo (P = .06), respectively, while leg oxygen consumption was around two-fold higher (P < .01) for salbutamol than for placebo (25±3 vs 14±1 mL×min-1). No treatment differences were observed in leg glucose uptake, lactate release, and oxygen consumption during exercise. But in recovery, cumulated leg glucose uptake, lactate release, and oxygen consumption was 21 mmol (95% CI: 18-24, P = .018), 19 mmol (95%CI: 16-23, P < .01), and 1.8 L (95% CI: 1.6-2.0, P < .01) higher for salbutamol than for placebo, respectively. Muscle glycogen content was around 30% lower (P < .01) for salbutamol than for placebo in recovery, whereas no treatment differences were observed in muscle glycogen resynthesis or glycogen synthase activity.Conclusions: Exercise blunts the effect of beta2-agonist on leg glucose uptake, but this attenuation diminishes in recovery. Beta2-agonist increases leg lactate release in recovery, which may relate to glycolytic trafficking due to excessive myocellular glucose uptake.
AB - Content: Exercise blunts the effect of beta2-agonist on peripheral glucose uptake and energy expenditure. Whether such attenuation extends into recovery is unknown.Objective: To examine the effect of beta2-agonist on leg glucose uptake and metabolic rate in recovery from exercise.Design: Using leg arteriovenous balance technique and analyses of thigh muscle biopsies, we investigated the effect of beta2-agonist (24 mg oral salbutamol) vs placebo on leg glucose, lactate, and oxygen exchange before, during, and 0.5-5-h in recovery from quadriceps exercise, as well as on muscle glycogen resynthesis and activity in recovery. Twelve healthy, lean young men participated.Results: Before exercise, leg glucose uptake was 0.42±0.12 and 0.20±0.02 mmol×min-1 (mean±SD) for salbutamol and placebo (P = .06), respectively, while leg oxygen consumption was around two-fold higher (P < .01) for salbutamol than for placebo (25±3 vs 14±1 mL×min-1). No treatment differences were observed in leg glucose uptake, lactate release, and oxygen consumption during exercise. But in recovery, cumulated leg glucose uptake, lactate release, and oxygen consumption was 21 mmol (95% CI: 18-24, P = .018), 19 mmol (95%CI: 16-23, P < .01), and 1.8 L (95% CI: 1.6-2.0, P < .01) higher for salbutamol than for placebo, respectively. Muscle glycogen content was around 30% lower (P < .01) for salbutamol than for placebo in recovery, whereas no treatment differences were observed in muscle glycogen resynthesis or glycogen synthase activity.Conclusions: Exercise blunts the effect of beta2-agonist on leg glucose uptake, but this attenuation diminishes in recovery. Beta2-agonist increases leg lactate release in recovery, which may relate to glycolytic trafficking due to excessive myocellular glucose uptake.
KW - Faculty of Science
KW - Thermogenesis
KW - Adrenoceptor
KW - Glycogenolysis
KW - cAMP
KW - PKA
KW - Beta-agonist
KW - Clenbuterol
U2 - 10.1210/clinem/dgab752
DO - 10.1210/clinem/dgab752
M3 - Journal article
C2 - 34665856
VL - 107
SP - e1193-e1203
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 3
ER -
ID: 282531877